Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**Gujie** is a Chinese prescription injectable product containing compound ossotide, an animal-derived peptide preparation made from extracts of healthy pig limb bones and whole scorpion. It is supplied as a sterile lyophilized preparation for injection and is manufactured by Heilongjiang Jiangshi Pharmaceutical. The product is indicated in China for symptomatic improvement in rheumatism, rheumatoid arthritis, osteoporosis, and cervical spondylosis, and to support bone healing after fractures and orthopedic surgery. Its pharmacology is not defined by a single molecular target; product information describes anti-inflammatory and analgesic activity and attributes bone-healing effects to a mixture of bone growth factors and peptides that may modulate bone metabolism, bone calcium handling, callus formation, and neovascularization. ([ypk.39.net](https://ypk.39.net/728511/manual/))
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on compound ossotide for injection.